Episode 51. Venetoclax in AML with Dr. Andrew Wei
Blood Cancer Talks
00:00
Advancements in AML Treatment: Venetoclax and Azacitidine
This chapter explores the impactful VLA study that led to the FDA approval of a combination treatment of azacitidine and venetoclax for older AML patients. It highlights the improved survival rates and the complexities of integrating this new therapy into clinical practice, including the management of risks and variations in physician approaches. Additionally, it discusses the significance of genetic mutations in treatment responses, emphasizing personalized management strategies for better patient outcomes.
Transcript
Play full episode
